{"id":2293,"date":"2023-06-25T17:55:36","date_gmt":"2023-06-25T17:55:36","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/zolpidem-tartrate\/"},"modified":"2023-06-25T18:01:07","modified_gmt":"2023-06-25T18:01:07","slug":"zolpidem-tartrate","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/zolpidem-tartrate\/","title":{"rendered":"Zolpidem tartrate"},"content":{"rendered":"

<\/p>\n

CLINICAL USE<\/h3>\n

Insomnia (short-term treatment)<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

5\u201310 mg at night<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           : 764.9<\/li>\n
  • %Protein binding                           : 92.5<\/li>\n
  • %Excreted unchanged in urine     : Negligible (56% as active metabolites)<\/li>\n
  • Volume of distribution (L\/kg)       : 0.34\u20130.54 (depends on age)<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      : Average: 2.4\/ Increased
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                : Not dialysed. Dose as in normal renal function<\/li>\n
  • HD                     : Not dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   : Unknown dialysability. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      : Not dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Antibacterials: metabolism accelerated by rifampicin<\/li>\n
  • Antipsychotics: enhanced sedative effects<\/li>\n
  • Antivirals: concentration increased by ritonavir (risk of extreme sedation and respiratory depression) \u2013 avoid concomitant use
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    First pass metabolism by liver is 35% Clearance is reduced in renal impairment .<\/li>\n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Insomnia (short-term treatment) DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-2293","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=2293"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2293\/revisions"}],"predecessor-version":[{"id":2307,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2293\/revisions\/2307"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=2293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=2293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=2293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}